R-chop
R-chop has been studied in 6 papers since 2021: 6 observational studies in people; 2 in the past year. The newest paper, May 19, 2026: “A Modified Simplified Frailty Score Predicts Survival, Toxicity, and Treatment Selection in Elderly Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Cohort Study”.
6 papers study it3 findingsUpdated
At a glance
The findings reach people, from one lab or study. 2 independent labs in 1 country; 58 trials, none about aging, 12 with no results posted.
“For fit patients, full-dose R-CHOP (initial dosage >80%) was associated with better survival than attenuated R-CHOP ([R-miniCHOP]; 2-year OS: 86% vs 70%; P = .012), also in adjusted analyses.”
1 of its findings points the other way.
- 2 independent labs in 1 country
- 1 finding against
- 58 trials, none about aging, 12 with no results posted
- Humans6
What did studies of r-chop find?
2Studies of r-chop measured 2 outcomes: survival and complete response.
Survival
no changein humans1upin humans1
1 study
Survival
no changein humans1upin humans1
R-chop was not clearly linked with survival in humans (unfit and frail patients with DLBCL).
Humansunfit and frail patients with DLBCL
R-chop is linked with better survival in humans (fit patients with DLBCL) (2-year OS: 86% vs 70%; P = .012).
Humansfit patients with DLBCL
Complete response
downin humans1
1 study
Complete response
downin humans1
R-chop is linked with lower complete response in humans (mSFS-fit patients, versus fit R-CHOP patients) (88% lower odds; aOR 0.12, p = 0.003).
HumansmSFS-fit patients, versus fit R-CHOP patientsdose-attenuated (R-mini-CHOP)
Has r-chop been tested in people?
0 of 58 about agingYes: 6 observational studies in people have been published, and 58 trials are registered.
In trials
Lymphoma, large b-cell, diffuse
Phase 4Completed25 trials
Phase 4Completed2 trials
Phase 3Active, not recruiting7 trials
Phase 3Completed7 trials
Phase 3Status unknown1 trial
Treatment na ve mantle cell lymphoma
Phase 3Completed1 trial
All 17Fewer
Readouts due
- Sep 2027
- Sep 30, 2027
Phase 1/2Active, not recruiting
Who is developing r-chop?
1 company: Beijing InnoCare Pharma Tech.
- Companies
- Beijing InnoCare Pharma TechPhase 3treatment na ve mantle cell lymphoma, diffuse large B-cell lymphoma
Trial sponsors
Company2 trialsPhase 3153 people
Company2 trialsPhase 1/2621 people
Company1 trialPhase 1/2150 people
Chia Tai Tianqing Pharmaceutical Group
Company1 trialPhase 1/290 people
Company1 trialPhase 1/272 people
Company1 trialPhase 156 people
1 trialPhase 450 people
4 trialsPhase 3466 people